residual disease

residual disease

Oncology Malignant cells or neoplasia that remains after any form–chemotherapy, surgery, RT–of 1º treatment
References in periodicals archive ?
This application is based on results from an open-label, randomized, global phase III clinical study (the KATHERINE study), evaluating efficacy and safety of Kadcyla adjuvant therapy compared to Herceptin in almost 1,500 people with HER2-positive early breast cancer who had invasive residual disease in the breast and/or axillary lymph nodes following neoadjuvant therapy including Herceptin.
Natera announced that the Palmetto MolDX program has proposed a local coverage determination, or LCD, for use of Natera's Signatera molecular residual disease test in patients with certain forms of colorectal cancer, or CRC.
THOUSAND OAKS, Calif., June 15, 2019 /PRNewswire/--Amgen (NASDAQ:AMGN) today announced the five-year overall survival (OS) analysis from the single-arm, Phase 2 BLAST study that evaluated BLINCYTO[R] (blinatumomab) in patients with minimal residual disease (MRD)-positive acute lymphoblastic leukemia (ALL).
Venclexta plus Gazyva showed deep and clinically meaningful responses characterized by a higher rate of minimal residual disease (MRD)-negativity in the bone marrow compared to Gazyva plus chlorambucil (MRD-negativity of 57 percent vs.
According to the company, Signatera is the first circulating tumour DNA (ctDNA) test custom-built for molecular treatment monitoring and molecular residual disease (MRD) assessment.
"His MRD (minimal residual disease), which looks for cancer in his bone marrow, has also come back clear.
SKMCH and RC uses MRD technology to identify the effectiveness of treatment and modification in cases of residual disease.
One patient treated with CTRT could tolerate the treatment well, but she could get only symptomatic relief from pain and bleeding, while the residual disease was persisting even after completion of re-radiation.
Background: Several studies have shown that detection of minimal residual disease (MRD) in acute myeloid leukemia (AML) is an independent prognostic factor.
With CWU surgery, residual disease can be monitored through the use of non-echo planar diffusion-weighted imaging (DWI) if second-look surgery is to be avoided.
WEDNESDAY, March 28, 2018 (HealthDay News) -- The detection of molecular minimal residual disease is associated with increased relapse rates in acute myeloid leukemia (AML), according to a study published in the March 29 issue of the New England Journal of Medicine.